Regeneron Pharmaceuticals (REGN) Revenue — Quarter Ended Dec 31, 2025
Revenue for the quarter increased compared to both the previous quarter and the same quarter a year earlier. The company reported higher revenue, continuing the positive trend seen throughout the year.
Key takeaway
Quarter ended Dec 31, 2025 · FY2025 Q4
Revenue for the quarter increased compared to both the previous quarter and the same quarter a year earlier. The company reported higher revenue, continuing the positive trend seen throughout the year.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$3.9B
Revenue reported for this quarter.
Quarter-over-quarter
+3.5%
Change from the immediately preceding quarter.
Year-over-year
+2.5%
Change from the comparable year-ago quarter.
Trailing four quarters
$14.3B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2025 | $3B | -3.7% |
| Jun 30, 2025 | $3.7B | +3.6% |
| Sep 30, 2025 | $3.8B | +0.9% |
| Dec 31, 2025 | $3.9B | +2.5% |
Revenue performance
The reported revenue was higher than in the prior three-month period, reflecting a sequential improvement. Year-over-year, revenue also increased, maintaining growth momentum.
Quarterly comparison
Compared to the immediately preceding quarter, revenue rose. When compared with the same quarter from one year earlier, revenue also grew.
What to watch
The company's fill/finish facility is undergoing process validation and has yet to be approved for commercial production, which may influence future supply capacity.